Cargando…

2958. Investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (NCDs), Tuberculosis (TB) recurrence, and other infections

BACKGROUND: TB continues to be a major cause of morbidity and mortality worldwide. Despite successful completion of anti-tuberculosis therapy (ATT), studies indicate that TB survivors (post-TB) have a significantly higher risk of mortality compared to the general population, primarily due to increas...

Descripción completa

Detalles Bibliográficos
Autores principales: Carrero Longlax, Santiago, DiNardo, Andrew, Portillo, Alexandra, Nishiguchi, Tomoki, Musher, Daniel M, Ginindza, Ntombifuthi, Mandalakas, Anna, gascua, Clement, Mulengwa, Durbbin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677615/
http://dx.doi.org/10.1093/ofid/ofad500.197
_version_ 1785150171467743232
author Carrero Longlax, Santiago
DiNardo, Andrew
Portillo, Alexandra
Nishiguchi, Tomoki
Musher, Daniel M
Ginindza, Ntombifuthi
Mandalakas, Anna
gascua, Clement
Mulengwa, Durbbin
author_facet Carrero Longlax, Santiago
DiNardo, Andrew
Portillo, Alexandra
Nishiguchi, Tomoki
Musher, Daniel M
Ginindza, Ntombifuthi
Mandalakas, Anna
gascua, Clement
Mulengwa, Durbbin
author_sort Carrero Longlax, Santiago
collection PubMed
description BACKGROUND: TB continues to be a major cause of morbidity and mortality worldwide. Despite successful completion of anti-tuberculosis therapy (ATT), studies indicate that TB survivors (post-TB) have a significantly higher risk of mortality compared to the general population, primarily due to increased incidence of non-communicable diseases (NCDs; cardiovascular disease, cancer, lung disease) and recurrent infections. Furthermore, a considerable proportion of TB patients exhibit persistent inflammation even after ATT. METHODS: We enrolled 325 individuals with microbiologically confirmed pulmonary TB, diagnosed between 2014 and 2020. Blood samples were obtained at baseline and 12- months (6-months after completing antimicrobial therapy) to evaluate persistent inflammation. Plasma C-reactive protein (CRP) was used to measure inflammation. Lipid peroxidation (LP) was measured by oxidized (HNE) LDL. Redox capacity was measured via the Trolox assay. Immune activation was measured by the Indoleamine 2,3 dioxygenases (IDO) enzyme by measuring the Kynurenine-Tryptophan ratio. RESULTS: After successful TB treatment, 62% of participants exhibited persistent elevation of CRP (P< 0.001) (Figure 1a). Univariate analysis of the first 186 participants revealed no association between elevated post-TB inflammation and HIV status (Fig. 1B), gender, or age. Individuals with increased CRP levels had a lower redox capacity compared to those whose CRP normalized at the end of ATT (P< 0.001) (Figure 2). Analysis of Oxidized LDL in successfully treated TB patients demonstrated that low antioxidant capacity also had persistent LP (Figure 2b). IDO activity was increased among TB participants with high CRP, which persisted even after successful therapy in participants with high and low CRP levels (Figure 3). Fig 1a: [Figure: see text] CRP was evaluated on TB participants and their asymptomatic, healthy household contacts. The median CRP of the healthy contacts was <2 mg/L, whereas the median CRP for TB participants at baseline was 21 and decreased to 8 at the end of successful therapy (EOT). Previous studies have demonstrated that CRP levels >3 mg/L are associated with increased CVD risk . 62% (111/186) of TB participants have CRP levels >3 mg//L at the end of TB therapy. Fig 1b: [Figure: see text] All TB participants living with HIV (PLWH) are started on ART, with >90% having a viral load <1000 at end of therapy (EOT). At EOT, TB participants without HIV do not have lower CRP levels compared to PLWHIV, preliminarily suggesting HIV is not driving the persistent inflammation. Fig2a: [Figure: see text] The Trolox antioxidant capacity was evaluated on TB Participants with High CRP >3mg/L (n:36) vs Low CRP <3mg/L (n:32) and Healthy Controls (n:32). CONCLUSION: This study shows that a substantial proportion of TB participants exhibit persistent inflammation and IDO activity even after ATT. Among TB participants who do not normalize inflammation at the end of successful therapy, there is also persistent LP and decreased redox capacity. This suggests that there is a bidirectional malignant relationship between LP and redox capacity. Potentially, this suggests that mitigating lipid peroxidation may help decrease post-TB inflammation. Fig2b: [Figure: see text] Oxidized LDL was measured in TB individuals with High levels of CRP High CRP >3mg/L (n:16) vs Low CRP <3mg/L (n:16) and Healthy Controls (n:4) Fig3 [Figure: see text] Plasma Kynurenine to Tryptophan ratio was evaluated in TB individuals with persistent augmented levels of CRP (n:19) at baseline and Heathy Controls. At the end of Therapy the KYN:TRYP was evaluated in TB individuals with high (n:22) and Low CRP levels (n:17) DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677615
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106776152023-11-27 2958. Investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (NCDs), Tuberculosis (TB) recurrence, and other infections Carrero Longlax, Santiago DiNardo, Andrew Portillo, Alexandra Nishiguchi, Tomoki Musher, Daniel M Ginindza, Ntombifuthi Mandalakas, Anna gascua, Clement Mulengwa, Durbbin Open Forum Infect Dis Abstract BACKGROUND: TB continues to be a major cause of morbidity and mortality worldwide. Despite successful completion of anti-tuberculosis therapy (ATT), studies indicate that TB survivors (post-TB) have a significantly higher risk of mortality compared to the general population, primarily due to increased incidence of non-communicable diseases (NCDs; cardiovascular disease, cancer, lung disease) and recurrent infections. Furthermore, a considerable proportion of TB patients exhibit persistent inflammation even after ATT. METHODS: We enrolled 325 individuals with microbiologically confirmed pulmonary TB, diagnosed between 2014 and 2020. Blood samples were obtained at baseline and 12- months (6-months after completing antimicrobial therapy) to evaluate persistent inflammation. Plasma C-reactive protein (CRP) was used to measure inflammation. Lipid peroxidation (LP) was measured by oxidized (HNE) LDL. Redox capacity was measured via the Trolox assay. Immune activation was measured by the Indoleamine 2,3 dioxygenases (IDO) enzyme by measuring the Kynurenine-Tryptophan ratio. RESULTS: After successful TB treatment, 62% of participants exhibited persistent elevation of CRP (P< 0.001) (Figure 1a). Univariate analysis of the first 186 participants revealed no association between elevated post-TB inflammation and HIV status (Fig. 1B), gender, or age. Individuals with increased CRP levels had a lower redox capacity compared to those whose CRP normalized at the end of ATT (P< 0.001) (Figure 2). Analysis of Oxidized LDL in successfully treated TB patients demonstrated that low antioxidant capacity also had persistent LP (Figure 2b). IDO activity was increased among TB participants with high CRP, which persisted even after successful therapy in participants with high and low CRP levels (Figure 3). Fig 1a: [Figure: see text] CRP was evaluated on TB participants and their asymptomatic, healthy household contacts. The median CRP of the healthy contacts was <2 mg/L, whereas the median CRP for TB participants at baseline was 21 and decreased to 8 at the end of successful therapy (EOT). Previous studies have demonstrated that CRP levels >3 mg/L are associated with increased CVD risk . 62% (111/186) of TB participants have CRP levels >3 mg//L at the end of TB therapy. Fig 1b: [Figure: see text] All TB participants living with HIV (PLWH) are started on ART, with >90% having a viral load <1000 at end of therapy (EOT). At EOT, TB participants without HIV do not have lower CRP levels compared to PLWHIV, preliminarily suggesting HIV is not driving the persistent inflammation. Fig2a: [Figure: see text] The Trolox antioxidant capacity was evaluated on TB Participants with High CRP >3mg/L (n:36) vs Low CRP <3mg/L (n:32) and Healthy Controls (n:32). CONCLUSION: This study shows that a substantial proportion of TB participants exhibit persistent inflammation and IDO activity even after ATT. Among TB participants who do not normalize inflammation at the end of successful therapy, there is also persistent LP and decreased redox capacity. This suggests that there is a bidirectional malignant relationship between LP and redox capacity. Potentially, this suggests that mitigating lipid peroxidation may help decrease post-TB inflammation. Fig2b: [Figure: see text] Oxidized LDL was measured in TB individuals with High levels of CRP High CRP >3mg/L (n:16) vs Low CRP <3mg/L (n:16) and Healthy Controls (n:4) Fig3 [Figure: see text] Plasma Kynurenine to Tryptophan ratio was evaluated in TB individuals with persistent augmented levels of CRP (n:19) at baseline and Heathy Controls. At the end of Therapy the KYN:TRYP was evaluated in TB individuals with high (n:22) and Low CRP levels (n:17) DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677615/ http://dx.doi.org/10.1093/ofid/ofad500.197 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Carrero Longlax, Santiago
DiNardo, Andrew
Portillo, Alexandra
Nishiguchi, Tomoki
Musher, Daniel M
Ginindza, Ntombifuthi
Mandalakas, Anna
gascua, Clement
Mulengwa, Durbbin
2958. Investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (NCDs), Tuberculosis (TB) recurrence, and other infections
title 2958. Investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (NCDs), Tuberculosis (TB) recurrence, and other infections
title_full 2958. Investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (NCDs), Tuberculosis (TB) recurrence, and other infections
title_fullStr 2958. Investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (NCDs), Tuberculosis (TB) recurrence, and other infections
title_full_unstemmed 2958. Investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (NCDs), Tuberculosis (TB) recurrence, and other infections
title_short 2958. Investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (NCDs), Tuberculosis (TB) recurrence, and other infections
title_sort 2958. investigating the mechanisms of persistent inflammation and the association with non-communicable diseases (ncds), tuberculosis (tb) recurrence, and other infections
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677615/
http://dx.doi.org/10.1093/ofid/ofad500.197
work_keys_str_mv AT carrerolonglaxsantiago 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections
AT dinardoandrew 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections
AT portilloalexandra 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections
AT nishiguchitomoki 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections
AT musherdanielm 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections
AT ginindzantombifuthi 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections
AT mandalakasanna 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections
AT gascuaclement 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections
AT mulengwadurbbin 2958investigatingthemechanismsofpersistentinflammationandtheassociationwithnoncommunicablediseasesncdstuberculosistbrecurrenceandotherinfections